Open AccessClinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases
Author(s) -
S. R. Gilarevsky
Publication year - 2021
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2021.4.n1549
Subject(s) - type 2 diabetes mellitus , medicine , diabetes mellitus , glucagon like peptide 1 , receptor , glucagon like peptide 1 receptor , glucagon , type 2 diabetes , endocrinology , pharmacology , agonist , insulin
The article discusses issues of reducing the risk for cardiovascular diseases (CVDs) in patients with type 2 diabetes mellitus during the treatment with modern hypoglycemic drugs, specifically glucagon-like peptide-1 receptor agonists.